



Vita Life Sciences Limited

ACN 003 190 421

ABN 35 003 190 421

Corporate Office

1/102 Bath Road,
Kirrawee NSW 2232

P.O. Box 3143

Kirrawee NSW 2232

T/Free: 1800 852 222

T: 02 9545 2633

F: 02 9545 1311

vitalifesciences.com

22 May 2024

Market Announcements
Australian Securities Exchange Ltd
20 Bridge Street
Sydney, NSW 2000

Dear Sir/ Madam,

2024 ANNUAL GENERAL MEETING (AGM)-ADDRESS & PRESENTATION

The Vita Life Sciences Ltd addresses to the 2024 AGM by the Chairman and the Managing Director with related presentation is attached.

This announcement has been authorised for release by the Board.

Yours faithfully,

A handwritten signature in black ink, appearing to read 'Chin L Khoo'.

Chin L Khoo
Company Secretary
Email: enquiries@vitalifesciences.com.au



Vita Life Sciences Limited – 2024 Annual General Meeting

Chairman’s Script - 22 May 2024

Welcome

Good afternoon ladies and gentlemen. I’m Henry Townsing, the Chairman of Vita Life Sciences Limited and the Chairman for the Annual General Meeting today.

Welcome to the VLS 2024 Annual General Meeting.

We are conducting this AGM in a hybrid manner, whereby shareholders can either attend in person or via teleconference. If you experience any difficulties with your connection to the AGM, you may contact our share registry, Automic on 1300 288 664.

It is now just after 12 pm and, there being a quorum present, I declare the meeting has been properly constituted and open for business.

Introduction

I have pleasure in introducing my fellow Directors who are in attendance:

- Andrew O’Keefe, our Managing Director;
- Jack Teoh, a non-executive Director; and
- Peter Osborne, our recently appointed non-executive director

Also present is our Company Secretary and CFO, Mr Chin Khoo and the Company’s external auditor representative, Mr Stephen Fisher the audit partner from Nexia. There will be opportunity for shareholders to ask questions to the Auditor as well as the Board on financial and business matters later in the meeting.

OUTLINE OF MEETING

Our business begins with the Managing Director’s presentation and, then the formal items of business as set out in the Notice of Meeting.

As this meeting is being conducted as a hybrid meeting, I would like to welcome those shareholders that are joining us online and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your screen. When you submit a question or comment, please start by typing which resolution it relates to so that it can be addressed at the appropriate time.

Questions which relate to the general business of the Company will be collected and addressed after the close of the formal business of the meeting.

I will now hand over the meeting to Andrew O'Keefe, our Managing Director who will be presenting a report on the Company's business.

Andrew O'Keefe

Thank you, Henry for the introduction.

AGENDA 1 MANAGING DIRECTORS PRESENTATION

Refer to Managing Directors Presentation

[Upon Completion of MD's Presentation Andrew, hands the conduct of the meeting to the Chairman]

AGENDA 2 RESOLUTIONS

Thank you, Andrew for that presentation. We shall now commence the formal business of the meeting.

The Notice of Annual General Meeting was mailed to all registered members on or about 19 April 2024 and is to be taken as read. Voting on all resolutions, will be conducted by poll.

For the purposes of the poll, I appoint the representative of Automic, the Company's share registry, who has examined and prepared summaries of the proxy forms received, to act as Returning Officer and to conduct the poll.

Shareholders in attendance online who have **already submitted their votes by proxy** should note that your votes will already be counted towards the poll. You do not need to lodge another vote unless you wish to change your votes.

Shareholders in attendance online who have **not submitted their votes by proxy** and wish to vote on the resolutions being put to the meeting today can do so by following the instructions provided in the Notice of Meeting. On your screen, there are instructions for how to log into the online voting portal.

Please note that the online voting portal is now open and will remain open until the poll is declared closed. Your votes must be submitted prior to the poll being closed for them to count. You should only submit your votes once by clicking "NEXT", AFTER the voting is concluded at the end of all the six resolutions. We will allocate sufficient time at the end of the final resolution for shareholders to submit their votes.

The proxies have been inspected and all those validly lodged have been accepted.

Proxies have been received representing up to 37,163,975 Shares or around 66% of the issued capital of the Company.

All undirected proxies or open votes that have nominated the Chairman of the Meeting as their proxy, will be cast in favour of each resolution in the Notice of the AGM.

We will now proceed to the resolutions set out in the Notice of AGM.

Financial Statements and Reports of Directors and Auditors

I turn now to the first item of business on the agenda, the consideration of the Financial Statements and Reports. The financial report and the reports of the directors and the

auditors are now laid before the meeting. There will be no vote on this item as it is a discussion item only.

The Company's auditor for the 2023 financial year, **Mr Stephen Fisher** of Nexia Sydney Audit Pty Ltd is present to take questions relevant to the conduct of the audit and the preparation and content of the independent auditor's report.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

Is there any discussion or questions on the 2023 Financial Reports?

Are there any questions relevant to the conduct of the audit and the preparation and content of the auditor's report to be put to the auditor?

[PAUSE AND TAKE QUESTIONS]

If there are no further question, I declare that the reports have been received and considered at this meeting.

Remuneration Report

In accordance with the Notice of Meeting, I now move onto item 2, Resolution 1 which is as follows:

*To consider and, if thought fit, to pass, with or without amendment, **Resolution 1**, Adoption of the Remuneration Report for the Financial year ended 31 December 2023, as an **ordinary resolution**.*

I note that while the vote on this item is advisory only and does not bind the Company nor its directors, the Board and Remuneration Committee takes into consideration the feedback we receive from shareholders.

An explanation of the item is to be found on page 9 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Members of the Company's key management personnel who were named in the FY2023 remuneration report and their closely related parties are reminded that they may not vote on this resolution.

Shareholders may now vote on Resolution 1. May I again remind shareholders not to click on "NEXT", until all seven the resolutions have been voted on.

If there are no further questions I will move to the next resolution.

Resolution 2: Re-election of Director – Mr Jack Teoh

I put forward Resolution 2:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 2**, as an **ordinary resolution**.

"That Jack Teoh, a director retiring by rotation in accordance with rule 5.1 of the Constitution, being eligible and having consented to act, be re-elected as a director of the Company."

An explanation of Resolution 2 and information on Mr Teoh is found on page 10 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 2. May I again remind shareholders not to click on "NEXT" until all the seven resolutions have been voted on.

If there are no further questions I shall move to the next resolution.

Resolution 3: Re-election of Director- Mr Peter Osborne

To consider and, if thought fit, to pass, with or without amendment, **Resolution 3**, as an **ordinary resolution**.

“That Peter Osborne, a director retiring in accordance with rule 8.2 of the Constitution, being eligible and having consented to act, be re-elected as a director of the Company.”

An explanation of Resolution 3 and information on Mr Osborne is found on page 10 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 3. May I again remind shareholders not to click on “NEXT” until all the seven resolutions have been voted on.

If there are no further questions I shall move to the next resolution.

Resolution 4: Share-Buy Back

I put forward Resolution 4:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 4**, as an **ordinary resolution**.

“That pursuant to and in accordance with section 257C of the Corporations Act 2001 (C'wlth), as amended, Rules 7.29 and 7.33 of the Listing Rules of ASX Limited, and for all other purposes, the shareholders approve, with effect from when the Directors make the relevant

announcement to the ASX, the on-market buy-back of up to 15% of the fully paid ordinary shares in the Company expiring on whichever is the earlier of the anniversary of the passage of this resolution or the 2025 Annual General Meeting and otherwise on the terms and conditions set out in the Explanatory Statement accompanying the 2024 Annual General Notice of Meeting at which this resolution is to be put.”

An explanation of Resolution 4 and information the share buy-back, is found from page 11 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 4. I again remind shareholders not to click on “NEXT” until all the seven resolutions have been voted on.

If there are no further questions I shall move to the next resolution.

Resolution 5: Approval to Replace Constitution

I put forward the following motion under Resolution 5:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 5**, as a **special resolution**.

“That pursuant to section 136(2) of the Corporations Act and for all other purposes, the members of the Company approve to repeal its existing constitution and adopt a new constitution in its place in the form as signed by the chairman's of the Meeting for identification purposes, with effect from the close of the Meeting.”

An explanation of Resolution 5, is found from page 13 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A. **[PAUSE AND TAKE QUESTIONS]**

Shareholders may now vote on Resolution 5. I again remind shareholders not to click on “NEXT” until all the seven resolutions have been voted on.

If there are no further questions I shall move to the next resolution.

Resolution 6: Long Term Incentive Plan

I put forward the following motion under Resolution 6:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 6**, as an **ordinary resolution**.

“That, for the purposes of ASX Listing Rule 7.2 (Exception 13(b)), and for all other purposes, the 2024 Long Term Incentive Plan and the issue of equity securities under the 2024 Long Term Incentive Plan be approved.”

An explanation of Resolution 6, is found from page 14 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 6. I again remind shareholders not to click on “NEXT” until all the seven resolutions have been voted on.

If there are no further questions I shall move to the next resolution.

Resolution 7: Long Term Incentive Plan: Grant of A Limited Recourse Loan to a Director to Purchase Ordinary Shares

I put forward the following motion under Resolution :

To consider and, if thought fit, to pass, with or without amendment, **Resolution 7**, as an **ordinary resolution**.

“That pursuant to ASX Listing Rules 10.14 and in accordance with Vita Life Sciences Limited’s “2024 Long Term Incentive Plan” (2024 Long Term Incentive Plan), tabled by the Chairman and initialled by him for purposes of identification, approval is given for the Directors to issue 300,000 new ordinary, fully paid shares in the Company and make a limited recourse loan to Mr Andrew O’Keefe, acting in his capacity as the Director of the Company, for a sum of \$690,000 (Loan), which will be used to fund the purchase of shares, on the terms summarised in the Explanatory Statement accompanying the Notice of 2024 Annual General Meeting.”

An explanation of Resolution 7, is found from page 16 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 7. I again remind shareholders not to click on “NEXT” until all the seven resolutions have been voted on.

If there are no further questions I shall move to the next item.

Can all shareholders voting online please ensure that you have submitted your votes – I will allow another minute before declaring the poll is closed. If you have any questions in relation to the submission of online votes, please send them through the Q&A function now.

I will now pause for about one minute to allow shareholders time to finalise and, submit their votes online.

Pause for a minute

There being no further questions I now declare voting is closed. The staff of Automic will now process the poll and the results will be announced to the ASX once they are available.

AGENDA 3 OTHER BUSINESS & QUESTION TIME

Is there any other business that can lawfully be brought forward?

[PAUSE TO CONSIDER]

If there are none, I now invite shareholders to forward any questions for management or the auditor via the Q&A.

[PAUSE AND TAKE QUESTIONS]

MEETING CLOSE

There being no further questions or matters for discussion, I'd like to thank all shareholders for their attendance and will now end the today's meeting. I declare the meeting closed.

Vita Life Sciences Limited – 2024 Annual General Meeting

Address by the Managing Director – 22nd May 2024

Opening remarks

Thank you, Henry.

Good afternoon and a warm welcome to all shareholders, VLS directors and the Executive Team.

Thank you for joining the Company's Annual General Meeting. It is my pleasure to provide you with an update on the Company's performance and insights into our strategic priorities moving forward.

As mentioned in my annual report address, the complementary medicines industry continues to show resilience, even in tough economic times. This resilience is evident in the overall category growth and our Company's performance over the past 12 months. The health and wellbeing of consumers remain a key consideration in the consumption of vitamins and supplements.

The VLS Group is well-positioned to leverage this demand by providing accessible, trusted, premium and innovative products across all markets.

Business Operations Overview

From our early origins in Singapore and Malaysia, our business has grown steadily into one of Australia's and Southeast Asia's leading natural healthcare organisations.

The Group enjoys distribution coverage spanning seven countries and is one of the few businesses in this category listed on the Australian Stock Exchange. All products within our portfolio are produced with the highest quality standards in both sourcing and manufacturing, supported by both scientific and traditional evidence.

Financial Performance

Turning to our 2023 full-year performance:

The VLS Group delivered record sales of \$74.2 million, up 11% from the prior corresponding period (PCP), and a pre-tax profit of \$12.5 million, up 16% from the PCP of \$10.7 million.

Our balance sheet remains strong, with total equity of \$43.3 million, up from \$36.5 million, and net cash of \$24.6 million, without any borrowings.

Based on sustained margins and profit performance, we declared a total dividend payment of 9.00 cents per share for FY23, up 50% on PCP.

Global Market Contributions

In terms of geographical market contributions, the FY23 revenue mix changed marginally from FY22; Australia is now the single largest market, increasing from 56% to 59%, which includes export to China. This increase was driven mainly by higher export contributions from a combination of marketing activities, higher consumer demand, and continued channel expansion across the Australian Pharmacy channel. Increased brand awareness among domestic and international

consumers is extremely encouraging and will underpin the Group's growth expectations moving forward.

Our strategic partnership in China continued to generate revenue growth through cross-border e-commerce (CBEC) activities and unsophisticated Daigou trading. China's performance across traditional e-commerce platforms will remain a fluid environment, requiring ongoing flexibility in both product selection and marketing tactics.

The Asia Pacific region, representing 41% of our Group's revenue, remains a significant strategic pillar for VLS in terms of risk diversity and brand expansion. Markets such as Vietnam and Indonesia will be key growth areas for the business in both the medium and long term.

Awards and Recognition

Our performance is best measured by market and consumer feedback. Over the past 24 months, our organisation has received numerous awards and recognitions. These accolades reflect our ongoing commitment to the purpose and values of our organisation and positively influence the health outcomes of our consumers. We are extremely proud of these recognitions and motivated to exceed future expectations.

Vietnam Expansion

The Herbs of Gold brand recently launched nine products in the Vietnamese market. This marks the beginning of a strategic partnership with Con Cung Group, a chain of Mother and Baby stores with over 700 outlets nationwide. From our first meeting, it was clear that our Company values and cultures were in perfect harmony, providing a strong foundation for our collaboration. While building the brand will require time and ongoing investment, we are enthusiastic about the long-term prospects of this market.

Marketing Efforts

Our marketing reach is extensive. While we haven't traditionally invested heavily in above-the-line spend, we have been extremely effective in showcasing both the Herbs of Gold and VitaHealth brands. Our brand presence across social media, digital, e-commerce, in-store and outdoor marketing activations is second to none. A visual representation has been provided to showcase a small sample of our activities, driving increased brand awareness and recall among consumers.

Strategic Priorities

The Company continues to demonstrate prudent financial discipline. Our business maintains a strong balance sheet and an even stronger cash position. We will continue to invest across key strategic pillars and leverage market potential.

The business has a consistent history of delivering on our long-term strategic goals. We have implemented several new initiatives to drive and support these key pillars and growth targets, including:

- Increased penetration across the pharmacy channel in Australia with the Herbs of Gold brand now available in 1,600 pharmacies, representing a significant portion of Australia's domestic revenue.
- Launching a new training portal scheduled for FY24, emphasising training and education as key differentiators.

- Continued investments across major e-commerce platforms to leverage Chinese consumer demand.
- Expanding the VitaHealth brand into modern trade pharmacies across Malaysia and Singapore.
- Launching the Herbs of Gold range into Con Cung through an exclusive strategic partnership.

Over the next 12 months, we will continue to build on our four key strategic pillars, reinvesting in the business to positively impact our financial performance.

I would like to take this opportunity to acknowledge our brilliant team across the entire Group. Their ongoing commitment and dedication have helped deliver record sales performance and increased dividends for shareholders.

Outlook

Shareholders can remain confident in the Company's future. The Group is well positioned to leverage market opportunities across the region. Our strategic plan remains robust, aiming to deliver future growth.

The business continues to track well against expectation thus far in FY24. With that in mind, market guidance will be provided mid-June for the first half.

In closing, I would like to thank all our shareholders and customers once again; without them, we wouldn't be in the strong position we are today.

Thank you for your attention. I will now hand the meeting back to the Chairman.

Andrew O'Keefe
Managing Director



Annual General Meeting

22 May 2024



Agenda

1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTIONS & ANSWERS

Henry Townsing

Chairman

Mr Townsing brings over 30 years' experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011. Mr Townsing was appointed as the Chairman of the Company effective 28th May 2021 and is also the chairman of the Company's Board Nomination and Remuneration Committees.



Agenda

1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTIONS & ANSWERS



Andrew O'Keefe Managing Director

Mr O'Keefe was appointed Managing Director on 1st January 2017. Prior to his Managing Director appointment, Mr O'Keefe was the Chief Executive Officer of Herbs of Gold Australia. He has over 20 years' experience within the Australian pharmaceutical and healthcare industry. During his career Mr O'Keefe has held senior leadership positions in publicly listed companies and was the CEO of Australia's largest health food distributor and retailer.

A Snapshot of the Vita Life Sciences Group



One of Australia's & South East Asia's leading natural healthcare brands

AU**74M+**

AUD74M+ in annual net revenue; strong balance sheet



High quality standards in sourcing & manufacturing



Over 350+ premium healthcare & pharmaceutical products



Over 400 employees across Australia & Asia



Multi-award winning brands



ASX publicly listed company



Formulas backed by scientific & traditional evidence



International brands in 7 markets



Over 75+ years experience in the health industry

Financial Performance



RECORD SALES

\$74.2M, UP 11%



PRE-TAX PROFIT

\$12.5M, UP 16%



BALANCE SHEET EQUITY


\$43.3M, NET CASH \$24.6M
(WITHOUT ANY BORROWINGS)



DIVIDEND PAYMENT

9.00 CENTS/SHARE,
UP 50%

Global Performance and footprint





Our awards

Australia

VOICE OF THE CUSTOMER
ADVANTAGE PHARMACY PROGRAM 2023
BEST COMPLEMENTARY MEDICINE BRAND
NATURALLY GOOD AWARDS 2023
VITAMIN SUPPLIER OF THE YEAR
WHOLELIFE AWARDS 2022
SUPPLIER OF THE YEAR
WHOLELIFE AWARDS 2022
SUPPLIER OF THE YEAR, SUPPLY CHAIN
RETAIL – NATIONAL PHARMACIES 2022
SUPPLIER OF THE YEAR
GO VITA 2022

Malaysia

BEST BRAND
STAR OUTSTANDING BUSINESS AWARDS 2023
MOST WANTED SUPPLEMENT FOR SKIN BRIGHTENING
WATSONS HWB AWARDS 2023
BEST EYECARE SUPPLEMENT
GUARDIAN AWARDS 2023
BEST ANTI-INFLAMMATORY SUPPLEMENT
ALPRO VIP'S CHOICE AWARDS 2023
BEST EYECARE SUPPLEMENT FOR KIDS
BABYTALK MAMAPAPA AWARDS 2023
BEST MENTAL WELLNESS SUPPLEMENT
NATURAL HEALTH AWARDS 2023
LEADING HEALTH SUPPLEMENT EXCELLENCE
ASEAN OUTSTANDING BUSINESS AWARDS 2023
SUPERBRANDS MALAYSIA 2022

Singapore

SINGAPORE CONSUMERS' CHOICE 2023/2024
SINGAPORE MARKETING EXCELLENCE AWARD 2023
RADIANCE AWARD, EYE CARE SUPPLEMENTS
GUARDIAN AWARDS 2023
TOP SELLER, TURMERIC SUPPLEMENT
– UNITY POPULAR CHOICE AWARDS 2023
SME EXCELLENCE BUSINESS AWARD 2022/2023
SINGAPORE CONSUMERS' CHOICE 2022/2023



herbs of gold™


Vietnam market
launch



Marketing Reach


herbsofgold™

VitaHealth™




Strategic priorities

Our pillars



Key initiatives to support our pillars





Outlook

- Driving brand performance across our respective markets will be paramount to the ongoing business trajectory
- Our product proposition and channel strategies across our respective markets remains robust
- The business continues to track well against expectations in FY24
- Management remains confident is delivering ongoing shareholder value and returns
- Half year guidance will be provided mid June



Thank you



Agenda

1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTIONS & ANSWERS

Resolutions

1. Remuneration Report
2. Re-election of Director – Jack Teoh
3. Re-election of Director- Peter Osborne
4. Share buy back
5. Approval to replace Constitution (Special)
6. Long Term Incentive Plan
7. Long Term Incentive Plan: Grant of a limited recourse loan to a Director to purchase ordinary shares

Proxy-Resolution 1

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
1	Adoption of the Remuneration Report	4,649,562	73,522	22,739,245	9,673,293

Proxy-Resolution 2

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
2	Re-election of Director (Jack Teoh)	14,398,666	26,064	22,739,245	0

Proxy-Resolution 3

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
3	Re-election of Director (Peter Osborne)	14,402,815	21,915	22,739,245	0

Proxy-Resolution 4

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
4	Share buy-back	14,386,559	34,395	22,739,728	0

Proxy-Resolution 5 (Special)

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
5	Approval to replace Constitution	14,378,008	34,901	22,739,728	0

Proxy-Resolution 6

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
6	Long Term Incentive Plan	4,652,766	71,335	22,739,245	9,673,293

Proxy-Resolution 7

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
7	Long Term Incentive Plan: Grant of a limited recourse loan to a Director to purchase ordinary shares	4,643,199	80,152	22,739,728	9,673,293

Proxy

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
1	Adoption of the Remuneration Report	4,649,562	73,522	22,739,245	9,673,293
2	Re-election of Director (Jack Teoh)	14,398,666	26,064	22,739,245	0
3	Re-election of Director (Peter Osborne)	14,402,815	21,915	22,739,245	0
4	Share buy-back	14,386,559	34,395	22,739,728	0
5	Approval to replace Constitution	14,378,008	34,901	22,739,728	0
6	Long Term Incentive Plan	4,652,766	71,335	22,739,245	9,673,293
7	Long Term Incentive Plan: Grant of a limited recourse loan to a Director to purchase ordinary shares	4,643,199	80,152	22,739,728	9,673,293

Agenda

1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTIONS & ANSWERS



Disclaimer

This document has been prepared by Vita Life Sciences Limited (**Vita Life Sciences**) and comprises written material/slides for a presentation concerning Vita Life Sciences.

The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Vita Life Sciences that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct, Except for any statutory liability which cannot be excluded, Vita Life Sciences and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Vita Life Sciences disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Vita Life Sciences since the date of this presentation.